DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Opitz G/BBB syndrome — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOpitz G/BBB syndrome maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for opitz g/bbb syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
midline 1 (MID1) — MID1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7QRY · 2.07 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Twelve Brazilian boys with Opitz G/BBB syndrome all had CNS midline anomalies: Dandy-Walker anomaly in two, enlarged cisterna magna in four, enlarged fourth ventricle in four, and callosal hypoplasia or aplasia in two. The 1992 report states these findings clearly show CNS midline involvement in the syndrome.
A 2005 Australian series of seven patients (five male, two female) managed over 25 years by a craniofacial unit found that all males presented with the classic triad of hypertelorism, cleft lip and palate, and hypospadias. Both females had hypertelorism, one had isolated cleft palate, and neither had genitourinary anomalies. The authors recommend coordinated multidisciplinary management but provide no quantitative outcomes data such as survival or complication rates.
A 2008 study of nine new patients with Opitz G/BBB features identified a novel MID1 mutation (c.1941insTGAGTCATCATCC) in one patient with hypertelorism, low-set ears, short philtrum, bilateral cleft lip and palate, and hypospadias. The authors note that MID1 mutations are found in only 47% of familial X-linked cases and 13% of sporadic cases, meaning most patients with the clinical diagnosis have no identifiable MID1 mutation.
A 2017 mechanistic study of the P151L mutation in the MID1 B-box1 domain shows that this mutation blocks interaction with the regulatory subunit α4, disrupting the MID1-α4-PP2Ac complex, while retaining B-box1 structure and E3 ligase activity. No clinical outcomes or therapeutic interventions are reported in any of these abstracts. What remains missing is any controlled trial of a drug, any quantitative long-term outcome data beyond case series, and any stratification of patients by genotype that might predict prognosis or response to intervention.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 1992 · 41 citations
CNS midline anomalies in the opitz G/BBB syndrome: Report on 12 Brazilian patients
AbstractWe report on 12 Brazilian boys with the Optiz G/BBB syndrome associated with CNS midline anomalies, namely, Dandy-Walker anomaly (two patients), enlarged cisterna magna (four patients), enlarged 4th ventricle (four patients), and callosal a/hypoplasia (two patients). These signs clearly show the involvement of the CNS midline in the Opitz G/BBB syndrome.
Multidisciplinary Management of Opitz G BBB Syndrome
AbstractOpitz G BBB syndrome is a rare condition characterized by the 3 major anomalies of hypertelorism, cleft lip and palate, and hypospadias, although there may be other associated anomalies. The underlying genetic causes are complex and consist of both X-linked recessive and autosomal dominant forms of the disorder. Previously, there have been publications on the underlying genetics and case reports, but there have been few reports regarding the long-term outcome. The aim in this study was to review the range of clinical presentation and evaluate outcomes of the multidisciplinary management of a cohort of patients with Opitz G BBB syndrome. In a 25-year period, 7 patients with Opitz G BBB syndrome were managed by the Australian Craniofacial Unit (ACFU), 5 male and 2 female. Most of the patients are now reaching skeletal maturity. Each one presented with a range of severity in the triad of hypertelorism, cleft lip and palate, and hypospadias anomalies. The males all exhibited the triad of anomalies, while the females both had hypertelorism, only 1 had isolated cleft palate, and neither had any genitourinary anomalies. Each patient underwent multidisciplinary assessment to make a treatment plan for staged management of different anomalies. Plan for surgical corrections of facial anomalies were performed according to the unit's protocol management of both hypertelorism and cleft lip and palate, but the presence of these coexisting anomalies required adjustment of the standard protocol of management of cleft lip and palate. In conclusion, we recommend that patients with Opitz G BBB syndrome require careful evaluation, and management of the anomalies should be in a coordinated manner by a multidisciplinary team.
American Journal of Medical Genetics Part A · 2008 · 14 citations
Clinical and molecular studies of patients with characteristics of Opitz G/BBB syndrome shows a novel <i>MID1</i> mutation
AbstractOpitz G/BBB syndrome is characterized by midline abnormalities such as hypertelorism, cleft palate, and hypospadias. This syndrome is heterogeneous with an X-linked recessive form caused by mutations in the MID1 gene at band Xp22.3. However, mutations in MID1 have only been identified in 47% of familial cases of X-linked Opitz G/BBB syndrome, and 13% of sporadic cases. We performed a phenotype-genotype analysis of a group of nine new patients with clinical characteristics commonly seen in Opitz G/BBB syndrome, and of previously reported patients. We identified a novel mutation in exon 9 of the MID1 gene, c.1941insTGAGTCATCATCC, leading to a premature termination codon at amino acid 514 in a patient with hypertelorism, apparently low-set ears, a short philtrum, bilateral cleft of lip and palate and hypospadias. This mutation affects the PRY domain of the C-terminus of the MID1 protein.
Mechanism of midline defect‐causing mutation P151L in <scp>MID</scp>1 revealed
AbstractThe P151L mutation in the B-box1 domain of MID1 causes midline defects in X-linked Opitz G Syndrome. MID1 is known to be a key regulator of phosphatase PP2A through formation of a complex with its catalytic (PP2Ac) and regulatory (α4) subunits. Wright et al. show that this mutation retains B-box1 domain structure and E3 ligase activity (star) but blocks interaction with α4, indicating disruption of the MID1-α4-PP2Ac complex.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
